Mesoblast limited (NASDAQ:MESO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday.
According to Zacks, “Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. “
Separately, Maxim Group restated a “positive” rating and issued a $14.00 target price on shares of Mesoblast limited in a research note on Wednesday, March 15th.
Shares of Mesoblast limited (NASDAQ:MESO) traded down 0.33% during trading on Tuesday, reaching $8.98. The company’s stock had a trading volume of 45,681 shares. The stock’s 50 day moving average price is $7.49 and its 200-day moving average price is $5.59. The stock’s market cap is $683.32 million. Mesoblast limited has a 52-week low of $3.50 and a 52-week high of $9.79.
An institutional investor recently raised its position in Mesoblast limited stock. Commerzbank Aktiengesellschaft FI raised its position in Mesoblast limited (NASDAQ:MESO) by 4.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,890 shares of the company’s stock after buying an additional 1,145 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Mesoblast limited were worth $139,000 as of its most recent filing with the SEC. 3.14% of the stock is currently owned by institutional investors.
Mesoblast limited Company Profile
Get a free copy of the Zacks research report on Mesoblast limited (MESO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com